IN8BIO, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
INAB$0.94+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(In thousands, except share and per share data)
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash | $27,092 | $11,120 |
| Prepaid expenses and other current assets | 788 | 1,458 |
| Total Current Assets | 27,880 | 12,578 |
| Non-current assets | ||
| Property and equipment, net | 1,858 | 2,858 |
| Restricted cash | 220 | 266 |
| Right-of-use assets - finance leases | 296 | 1,068 |
| Right-of-use assets - operating leases | 1,882 | 3,899 |
| Other non-current assets | 146 | 275 |
| Total Non-Current Assets | 4,402 | 8,366 |
| Total Assets | $32,282 | $20,944 |
| Liabilities and Stockholders' Equity | ||
| Liabilities | ||
| Current liabilities | ||
| Accounts payable | $309 | $389 |
| Accrued expenses and other current liabilities | 1,633 | 1,047 |
| Short-term finance lease liability | 295 | 694 |
| Short-term operating lease liability | 924 | 953 |
| Total Current Liabilities | 3,161 | 3,083 |
| Long-term finance lease liability | — | 295 |
| Long-term operating lease liability | 1,563 | 3,088 |
| Total Non-Current Liabilities | 1,563 | 3,383 |
| Total Liabilities | 4,724 | 6,466 |
| Commitments and Contingencies | ||
| Stockholders' Equity | ||
| Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024. No shares issued and outstanding | — | — |
| Common stock, par value $0.0001 per share; 490,000,000 shares authorized at December 31, 2025 and 2024; 9,766,132 and 2,416,066 shares issued and outstanding at December 31, 2025 and 2024, respectively(1) | 10 | 7 |
| Additional paid-in capital | 168,644 | 136,127 |
| Accumulated deficit | (141,096) | (121,656) |
| Total Stockholders' Equity | 27,558 | 14,478 |
| Total Liabilities and Stockholders' Equity | $32,282 | $20,944 |
(1)All share amounts and per share amounts disclosed in this Annual Report on Form 10-K have been restated to reflect a one-for-thirty reverse stock split effected in June 2025. See Note 1, Organization and Nature of Operations, for details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.